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Role of glucoregulatory hormones in potassium homeostasis
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An incompletely defined interregulatory balance
exists between potassium, insulin, and aldosterone.
That potassium administration enhances and hypo-
kalemia depresses aldoterone production is well
known. It is not as well known that the same relation-
ship exists between potassium and insulin. In a nor-
mal subject, acute hyperkalemia stimulates release of
insulin from the pancreas. Potassium deficiency, on
the other hand, may depress production of insulin.
Both insulin and aldosterone, under appropriate con-
ditions, may indirectly promote transfer of potassium
ions from extracellular to intracellular fluid. In con-
trast, deficiency of either insulin or aldosterone, and
expecially both, may favor development of hyper-
kalemia.
Pharmacologically, glucagon, epinephrine, norepi-
nephrine, and somatotropin may also influence
transfer of potassium between extracellular and intra-
cellular fluid. Their precise physiological roles in
potassium homeostasis, however, are much less evi-
dent than that for insulin and aldosterone.
It is the intention of this brief review to point out
the salient effects and mechanisms whereby the fore-
going substances affect potassium homeostasis and to
point out physiologically important interrelation-
ships wherever possible.
Hypokalemia induced by hyperglycemia or insulin
administration. It has been recognized for many years
that administration of glucose may be associated with
a decline in the concentration of potassium in both
serum and urine [1, 2]. It is now clear that hyper-
glycemia induced by administration of glucose in-
duces release of insulin from the beta cells of the pan-
creas. Insulin, released by the stimulus of hyper-
glycemia, or following its injection, promotes transfer
of potassium ions into several tissues, those of most
importance being the liver and skeletal muscle.
The capacity of insulin to promote transfer of po-
tassium into cells has considerable practical impor-
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tance. Therapeutically, it is a powerful tool for treat-
ment of acute hyperkalemia. On the other hand, its
action can produce disastrous cardiac arrhythmias in
a patient receiving digitalis if he should become
acutely hypokalemic.
When potassium ions are transported from the
extracellular fluid with glucose, their destiny inside
the cell is largely unknown. Harrop and Benedict
proposed that potassium is incorporated as a salt of a
phosphorylated carbohydrate [3]. Definitive in forma-
tion on this possibility is not available. It has also
been proposed that potassium is deposited as a com-
plex of glycogen, since during glycogenesis, it can be
shown that an approximately fixed quantity of potas-
sium is incorporated into tissue for each unit mass of
glycogen synthesized [4]. There is no positive evi-
dence, however, to support the notion that a potas-
sium-glycogen complex exists. Based upon electrical
phenomena, we would favor the view that in-
tracellular potassium for the most part exists as a free
ion in solution [5, 6].
Efjct of insulin on sodium and potassium transport.
In vitro studies have shown that insulin stimulates
effiux of sodium from human lymphocytes [7], rat
brain [8], uterus [9], and skeletal muscle of the frog
[10] and rat [II, 12]. It also favors retention of both
sodium and potassium by the kidney [13]. In associa-
tion with increased sodium efflux from these tissues,
insulin increases oxygen consumption [14, 15] and
lactate production by skeletal muscle, thus suggesting
utilization of energy for sodium transport.
Studies by Andres et al [16] and Zierler [17] have
shown that insulin-mediated potassium transfer in
muscle occurs independently of glucose. Using the
isolated extensor digitorum longus muscle of the rat,
they demonstrated that insulin produced a loss of
sodium and net accumulation of potassium. The
measured intracellular electronegativity, however,
rose before there was a detectable increase of tissue
potassium content. Furthermore, the final value of
the negative potential surpassed that which could
have accounted for the measured rise of intracellular
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potassium concentration [18]. Zierler concluded that
insulin hyperpolarized the muscle membrane by some
unexplained mechanism, that potassium transport
followed in its wake and was consequently dee-
trogenic.
More recent studies have confirmed earlier obser-
vations that insulin-stimulated sodium efflux from
frog muscle occurs independently of glucose trans-
port [19, 201. Moore, using sodium-loaded frog ske-
letal muscle, showed that insulin treatment stimu-
lated sodium etliux, decreased intracellular water
content, and increased intracellular potassium con-
centration [10]. Gavryck, Moore, and Thompson,
studying isolated sarcolemmal membranes from the
frog, obtained evidence that insulin increases the ac-
tivity of a magnesium-dependent, sodium-potassium-
adenosine triphosphatase (Na-K-ATPase) [8]. This
effect was quantitatively dependent upon sodium
concentration in the incubating medium. It could be
inhibited by either blocking the action of Na-K-
ATPase with ouahain, or by eliminating potassium
from the incubating medium. Large concentrations
of insulin could overcome ouabain inhibition. When
the concentrations of potassium and sodium were
raised sufficiently so that activity of the pump was
maximally stimulated, insulin had no additional stim-
ulatory effect. At lower concentrations of sodium,
however, the increased ATPase activity mediated by
insulin was readily detectable.
Kipnis and Parrish [12] suggested that transport of
sodium and amino acids mediated by insulin might
be closely related. They found that insulin-stimulated
transport of c-aminoisobutyric acid in the rat dia-
phragm was virtually abolished if sodium transport
were inhibited or if sodium were excluded from the
incubating solution.
There also exists a very interesting association be-
tween potassium and glycogen in skeletal muscle. A
normal quantity of potassium in muscle is necessary
for glycogen synthesis. Ouabain, an inhibitor of Na-
K-ATPase, also inhibits activation of glycogen syn-
thetase by insulin [21, 221. In potassium deficiency,
both storage and synthesis of glycogen are seriously
impaired [23]. As will be subsequently discussed, po-
tassium deficiency decreases the capacity to produce
insulin. In patients with insulin-deficient diabetes
mellitus, glycogen synthetase activity and glyeogen
content of muscle are also significantly less than nor-
mal. Both abnormalities return to normal after treat-
ment with insulin [24]. In potassium deficient skeletal
muscle, the concentration of sodium is abnormally
elevated and the resting membrane potential abnor-
mally low [251. It seems conceivable that at least
some of the abnormalities in potassium-deficient ske-
letal muscle could be the result of impaired transport
which, in turn, might result from insulin deficiency.
Adrenergic receptor function and serum potassium
concentration. Substantial evidence indicates that
acute stimulation of alpha-adrenergic receptors may
result in hyperkalemia. In contrast, acute stimulation
of heta-adrenergic receptors may cause hypokalemia.
Infusion of either epinephrine or norepinephrine i.v.
may cause acute transient hyperkalemia. Although
infusion of either substance may depress plasma in-
sulin [26], the hyperkalemic response to these cate-
cholamines occurs very rapidly and consequently is
probably not the result of an acute insulin lack.
Craig and Mendell [27] showed that hyperkalemia
induced by epinephrine is mediated by potassium
released from the liver. During epinephrine infusion,
potassium and glucose concentration rose in hepatic
venous blood but not in carotid arterial blood. The
a/pha-adrenergic blocker dibenamine prevented the
hyperkalemic response to epinephrine. Therefore, it
seems likely that hyperkalemia immediately after epi-
nephrine infusion results from a/pha-adrenergic stim-
ulation. Hyperglycemia induced by epinephrine is
followed by hypokalemia. Although the acute and
transient hyperkalemia induced by epinephrine does
not occur if an animal is pretreated with dibenzyline,
dibenamine, or phentolamine, the latter drugs do not
inhibit hyperglycemia [28].
Vick, Todd, and Leudke [291 examined the rela-
tionships between potassium transfers in liver and
skeletal muscle during epinephrine-induced hypo-
kalemia. During iv. infusion of epinephrine, they
showed that the hypokalernia could be reversed by
propranolol. Their studies also indicated that uptake
of potassium under the influence of epinephrine oc-
curred in both liver and skeletal muscle and that these
effects were mediated through beta-adrenergic recep-
tors.
Lum and Lockwood [30, 31] showed that both
nicotine and epinephrine exert a protective effect
against the hyperkalemia produced by infusion of
potassium chloride. The protection by both of these
agents is abolished by propranolol. Their data clearly
supported earlier evidence that heta-adrenergic stim-
ulation leads to uptake of potassium ions by skeletal
muscle cells. Of great importance, the beta-adrenergic
stimulation produced by epinephrine and its action to
protect against cardiotoxic hyperkalemia persists in
the pancreatectomized animal. That this eliminates
insulin as a mediator of hypokalemia induced by
epinephrine was predictable since epinephrine in-
fusion has been shown to inhibit release of insulin
[26]. The beta-adrenergic stimulator isoproterenol
also provides protection against hyperkalemia.
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In contrast to the effects of epinephrine, norepi-
nephrine induces a more modest increase of blood
glucose and does not cause hypokalemia [31]. These
effects correspond to the predominant alpha-adrener-
gic effect of norepinephrine.
The foregoing evidence has several implications.
First, certain adrenergic agents possessing beta-ad-
renergic receptor-stimulating properties might be
useful in the treatment of acute hyperkalemia. Such
treatment has been successfully used in patients with
hyperkalemic familial periodic paralysis [32]. Second,
agents tending to block potassium uptake by skeletal
muscle cells, such as propranolol, could well be useful
in managing certain hypokalemic states in which po-
tassium movement into muscle is accelerated, such as
periodic paralysis. Accordingly, three patients with
hypokalemic periodic paralysis associated with
thyrotoxicosis improved after propranolol treatment
[331. Third, certain patients receiving propranolol or
other beta-blockers could conceivably develop dan-
gerous hyperkalemia during at least five conditions:
insulin deficiency, renal failure, exercise, administra-
tion of potassium chloride, and while simultaneously
ingesting drugs, such as sprionolactone, which inter-
fere with the action of aldosterone. Indeed, in pa-
tients with uncomplicated essential hypertension,
treatment with beta-blockers has resulted in slight
elevation of serum potassium concentration [34, 351.
Frank hyperkalemia as a result of such therapy, how-
ever, has apparently not been reported.
Glucagon. In a pattern quite similar to that ob-
served during infusion of epinephrine, administration
of glucagon in pharmacologic doses may be followed
by acute hyperglycemia and hyperkalemia [28].
Glucagon has a potent glycogenolytic effect in the
liver but not in skeletal muscle [36]. Several very
interesting observations have been made concerning
the effect of glucagon. In Figure 1, it is shown that
these hyperglycemic and hyperkalemic responses may
be dissociated by repeated injection. In this study,
cats were injected with glucagon, 50sg/kg of body
wt, i.v., every 30 mm. As the liver became depleted of
glycogen, the hyperglycemic response became corre-
spondingly less. Nevertheless, the hyperkalemic re-
sponse persisted. This suggests that hyperkalemia af-
ter glucagon, although it is of hepatic origin [38], is
probably not the direct result of glycogenolysis.
Moreover, dibenamine inhibits the hyperkalemic ef-
fect of glucagon but does not alter its capacity to split
glycogen. Fasting for a sufficient period of time
to deplete hepatic glycogen eliminates the hyper-
glycemic effect of glucagon but not the hyperkalemic
effect [28]. Although glucagon-mediated release of
potassium from the liver is inhibited by the a-ad-
renergic blocker dibenamine, one cannot conclude
that glucagon is a specific a-adrenergic agonist. The
cited studies were done in intact animals. Therefore,
it is possible that glucagon might have facilitated
release of catecholamines which, in turn, caused the
hyperkalemia. That glucagon induces release of cate-
cholamines has been demonstrated [361.
Effct of glucagon on electrolyte excretion. When
glucagon is administered in quantities sufficient to
induce abnormally elevated concentrations in
plasma, the excretion of sodium, potassium, calcium,























Fig. I. Glucagon, 50 jig/kg, administered every 30 mm, hyperka-
lenjia occurring aJmer each dose. The hyperglycemic response pro-
gressively fell. These findings suggest that the hyperkalemic and
hyperglycemic responses to glucagon are independent. (Re-
produced through the courtesy of ELLIS S. BECKSTT SB, J Phar-
macol Exp Ther 142:3 18, 1963.)
Glucagon
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[371. Although the glomerular filtration rate may also
rise, the rise is not sufficient to account for the in-
crease in electrolyte excretion. Furthermore, the ef-
fect on electrolyte excretion is independent of hyper-
glycemia or glycosuria [381. Its effect is felt to be
primarily on the tubule itself [39].
The propensity of glucagon to increase electrolyte
excretion into the urine could have clinical relevance
when it is used in the treatment of congestive heart
failure [40]. Observations published in abstract form
[41] have shown that administration of I to 16 mg of
glucagon per hour for one to two days was associated
with modest hypokalemia. This did not occur if p0-
tassium supplements were given.
Endocrine response to hyperkalernia. Experimen-
tally, acute hyperkalemia produced by infusion of
potassium chloride induces a catharsis of several hor-
mones from their sites of storage. These include in-
sulin [42, 43], glucagon [42], aldosterone [44], growth
hormone [45], and catecholarnines [46]. In vitro
hyperkalernia may also promote release of luteinizing
hormone [451 and thyrotropin [481. Insulin, aldoste-
rone, growth hormone, and epinephrine possess the
capacity, at least indirectly, to transfer potassium
ions from the extracellular to the intracellular fluid.
Except for insulin and aldosterone, sufficient infor-
mation is not currently available to permit assess-
ment of other hormones as to their physiologic roles
in protection against hyperkalemia.
Grodksy and his coworkers were the first to ob-
serve that increased potassium concentration invitro
caused release of insulin [49, 50]. This effect is ob-
served even in the absence of glucose. It has also been
shown that extracellular sodium and an intact so-
dium pump are prerequisites for kaliogenic insulin
release [51]. Using pen fused isolated rat islets, Lam-
bert, Henquin, and Malvaux [52] showed that oua-
bain interfered with glucogenic as well as kaliogenic
insulin secretion. Subsequent in vivo studies in experi-
mental animals [42, 43] and human volunteers [45]
showed that hyperkalemia also elicits increased in-
sulin secretion in man. In the dog, elevation of serum
potassium by as little as 0.2 to 0.3 mEq/liter is suf-
ficient to induce insulin release [42, 53].
Dluhy, Axelrod, and Williams [45] studied ten hu-
man volunteers whose sodium intakes were either 10
mEq/day (N 5) or 200 mEq/day (N = 5). They
infused 75 mEq of potassium chloride over 120 mm
when dietary potassium intake was 40 mEq/day and
again when it was 200 mEq/day. Sodium intake had
no apparent effect. (This is a surprising observation:
in the rat, sodium restriction induces at least partial
potassium adaptation [59]). Studies were conducted
when balance was achieved. During infusion of po-
tassium chloride, maximum hyperkalemia was
slightly but significantly less when potassium intake
was 200 mEq/day than when it was 40 mhq/day.
While receiving a 40 mEq potassium intake, insulin
rose and plasma glucose fell when hyperkalemia (6.0
mEq/liter) was induced. In contrast, when dietary
potassium intake was 200 mEq, hyperkalemia (5.6
mEq/liter) did not induce a change in either plasma
glucose or insulin.
As discussed in the previous section of this review,
under conditions of acute hyperkalemia, increased
insulin most likely promotes transfer of potassium
ions into several tissues, the most important being
skeletal muscle and liver. The foregoing evidence sug-
gests that insulin plays a role in the immediate de-
fense against hyperkalemia. In experimental animals,
tolerance to hyperkalemia is severely impaired by
pancreatectomy or by administration of alloxan [42,
54, 55]. The capacity to dissipate acute hyperkalemia
in the insulin-deficient animal, however, can be re-
stored by insulin [54].
Hyperkalemia induced by infusion of potassium
salts is spontaneously corrected by excretion of po-
tassium into the urine, as well as temporary transfer
of potassium from extracellular to intracellular fluid.
Repeated bouts of hyperkalemia or steadily increas-
ing potassium in the diet leads to a state of potassium
adaptation [56—581. In this acquired state, acute loads
of potassium, which previously would have been
fatal, can be safely administered without harmful
effects. Strong evidence indicates that increased al-
dosterone production is at least one of the factors
involved in potassium adaptation [59]. A state of
potassium adaptation may well exist in advanced
renal failure [60]. Most patients with chronic renal
failure overproduce aldosterone [61]. They have the
capacity to excrete more potassium per unit of gb-
merular filtration rate than normal subjects [60].
They also tend to develop acute hyperkalemia during
administration of drugs interfering with the action of
aldosterone, such as spironolactone [62, 63]. The lat-
ter response underscores the importance of aldoste-
rone production in chronic renal failure.
In studies of potassium-adapted rats, we found
that plasma immunoreactive insulin concentration
was the same as that in control animals [64]. This and
the finding by Dluhy and his associates [451 on hu-
man subjects ingesting a diet containing 200 mEq of
potassium does not mitigate the role of insulin in the
defense against hyperkalemia in the potassium-
adapted state. Although highly speculative, a process
can be envisioned in which insulin is required to
facilitate adaptation of mechanisms to forestall hy-
perkalemia, perhaps specific potassium transport sys-
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tems. Once developed, acute elevations of insulin in
response to mild hyperkalemia may no longer be
required. Although equally speculative, it is possible
that the molecular species of insulin could be altered
in the potassium-adapted state in an opposite manner
to that shown to occur in potassium deficiency [65].
Under such conditions, plasma concentration per se
would not necessarily reflect activity. At any rate,
there is overwhelming evidence that either experi-
mental or clinical insulin deficiency interfers with
potassium tolerance.
Hyperkalemia in diabetes mel/itus. Since induction
of only slight hyperkalemia in a normal subject is
apparently counteracted by release of insulin, one
would predict that patients with insulin deficiency
under the same conditions might become more
hyperkalemic or at least display more prolonged
hyperkalemia. As indicated earlier, the ability to
counteract hyperkalemia is not only dependent upon
insulin secretion but also upon an intact adrenal cor-
tex, specifically requiring the ability to produce al-
dosterone. Since the onset of aldosterone action is
delayed, neither its production nor its effect would
appear to be emergency physiological mechanisms by
which acute hyperkalemia in a nonpotassium-
adapted subject is counterbalanced. Nevertheless,
adrenal insufficiency is associated with intolerance to
potassium, and the physiologic process of potassium
adaptation apparently cannot develop in the absence
of aldosterone production. The practical corollary of
this phenomenon is the propensity toward acute
hyperkalemia in patients with diabetes mellitus after
administration of drugs which interfere with the ac-
tion of aldosterone, such as triamterene [66].
Acute hyperkalemia sufficient to alter the electro-
cardiogram may also occur with hypertonicity of
plasma under certain conditions. Potassium concen-
tration in intracellular water is very high compared to
its concentration in extracellular water. A sudden
increase in osmotic activity outside a cell may in turn
induce an osmotic flow of water. Such a rapid flow of
water through cellular pores could be accompanied
by a flux of potassium ions (solvent drag). Under
normal conditions, such acute hyperkalemia would
be met by a rapid release of insulin, which in turn
would promote transport of potassium ions back into
the cell. Therefore, in normal subjects, significant
hyperkalemia as a result of acute hyperglycemia
would probably not occur. On the other hand, in
patients with insulin deficiency, it is not at all surpris-
ing that hyperkalemia would occur in the event of
acute hyperglycemia. Moreno, Murphy, and Gold-
smith [67] showed that mild hyperkalemia could be
similarly induced in normal subjects by sudden hyper-
tonicity incident to infusion of hypertonic mannitol
or sodium chloride. The effect of glucose was not
examined.
That such a response to hypertonicity may have
clinical relevance has recently been pointed out by
Goldfarb and his coworkers [68, 69]. Studying pa-
tients with diabetes mellitus associated with hypo-
reninemic hypoaldosteronim, they showed that acute
hyperglycemia could induce dangerous levels of
hyperkalemia. The latter did not occur under con-
ditions of optimum treatment with insulin and
mineralocorticoid.
More recently, evidence has been obtained by
Perez and his associates [70] showing that patients
with diabetes mellitus, and especially those who have
been previously hyperkalemic in association with
moderately advanced renal failure, display an ele-
vated serum potassium concentration during hyper-
glycemia induced by ingesting 100 g of glucose
during a glucose tolerance test. This response stands
in sharp contrast to the slight decline of serum potas-
sium induced by oral ingestion of glucose in this
quantity by a normal person.
The role of glucagon in acute hyperkalemia. Studies
conducted on dogs in this laboratory suggest that
glucagon may play an important role in the defense
against acute hyperkalemia [42]. Figure 2 illustrates
that hyperkalemia in the dog is promptly followed by
release of insulin from the pancreas. There is a simul-
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Fig. 2. In/usion o/poiassiu,n chloride (KCI) into normal dogs result-
ing in release ofboth insulin and glucagon. Plasma glucose concen-
tration remains normal. (Reproduced through the courtesy of













Fig. 3, Infusion of potassium chloride (KCI) into dogs viih experi-
mental diahejes Ine//itus induced by alloxan, requiringlesspota,ssiutn
to induce the same level of hj'perkalemia as observed in the normal
dog. In these dogs, glucagon rose during hyperkalernia and was
associated with progressive hyperglycemia. Insulin did not in-
crease. (Reproduced through the courtesy of SANTENSANIO et a!,
.1 Lab C/in Med 8 1:809, 1973.)
contention that glucagon probably induces glyco-
genolysis in the liver and thereby prevents acute
hypoglycemia which would otherwise occur in the
wake of insulin secretion. In support, Figure 3 shows
that plasma glucose rises during acute hyperkalemia
in the animal made insulin-deficient by previous ad-
ministration of alloxan. In the alloxan-treated ani-
mals, much less potassium chloride was required to
produce a similar degree of hyperkalemia than in
normal dogs.
Potassium, insulin, and glucagon during exercise. It
seems appropriate at this point to interject some ob-
servations made on the behavior of insulin and gluca-
gon and their relationship to serum potassium during
exhaustive physical exercise. Severe exercise is asso-
ciated with release of potassium ions from con-
tracting muscle cells in sufficient quantity to produce
acute hyperkalemia. This is usually not severe. Dur-
ing such exercise in the untrained subject, however,
potassium concentration in plasma may on occasion
become sufficiently elevated to produce electro-
cardiographic evidence of hyperkalemia [71]. Based
upon this observation, it has been suggested that
hyperkalemia-mediated arrhyth niias might be im-
plicated in the occasional sudden death associated
with massive exertion in the untrained subject. Al-
though one might expect that acute hyperkalemia
during exercise would be met by a release of insulin
from the beta cell, such is not the case [72]. We have
examined the relationship of serum potassium, im-
munoreactive insulin, immunoreactive glucagon, and
glucose during exhaustive exercise in dogs (Fig. 4).
During exercise there was a slow but progressive
increase in the concentration of potassium. Despite
hyperkalemia, insulin concentration fell. Glucose in-
creased despite the likelihood that its utilization was
greater. Glucagon showed a pronounced rise and was
probably at least partially responsible for the rise in
blood glucose concentration. Of interest, when the
exercise was stopped there was a sudden, sharp rise of
insulin. The reason why insulin levels in plasma do
not rise during exercise, despite hyperkalemia, is not
completely clear. However, it seems possible that al-
pha-adrenergic stimulation mediated by release of
catecholamines during intense exercise could possibly
prevent insulin release as well as stimulate release of
glucagon [26]. If the metabolic effect and secretion of
catecholamines were immediately dissipated upon
completion of exercise, then one could postulate that
the insulin rebound is kaliogenic. Insulin, in turn,
would dissipate the hyperkalemia by promoting po-
tassium transport into cells.
We have interpreted the foregoing alterations of
insulin and glucagon during exercise to be protective
in nature [72]. The rise of glucagon and the decline of
insulin would help provide an adequate supply of
glucose for the brain. In support of this notion, it was
also shown that infusion of glucose in small quan-
Time, mm
Fig. 4. Glucagon and glucose rising during exhaustive exercise, se-
rum poassiuu,. Insulin declines to low levels. Upon cessation of
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tities (15 mg/mm/kg of body wt), started before and
continued throughout exercise, prevented glucagon
release. Furthermore, in other animals fasted for a
sufficiently long time to deplete liver glycogen, com-
parable exercise was associated with release of gluca-
gon and maintenance of blood glucose at a satisfac-
tory level. Such avoidance of hypoglycemia during
exercise despite the absence of liver glycogen in-
dicates that glucose had to be derived by gluconeo-
genesis. It is possible that glucagon mediated this
process. The possibility that exercise-induced hyper-
kalemia might be the cause of glucagon release during
such exercise has not been conclusively demon-
strated.
Decreased insulin production and abnormal carbohy-
drate metabolism in potassium deficiency. That potas-
sium deficiency leads to a derangement of carbohy-
drate metabolism in man was first published by
McQuarrie, Zierler, and Johnson in 1937 [73, 741.
They described a patient with a "hypercorticoadrenal
syndrome" who displayed atypical diabetes mellitus,
hypertension, hypernatremia, hypokalemia, and evi-
dence that increased dietary sodium chloride wor-
sened the diabetes. This patient clearly resembles
primary aldosteronism, as described later by Conn,
Knopf, and Nesbit [75].
Following the introduction and clinical use of the
benzothiadiazine diuretics, several observers noted
that some patients became frankly diabetic. Shapiro,
Benedek, and Small [76] examined the effect of
chiorothiazide in IS hypertensive patients with
slightly abnormal glucose tolerance tests. Fifteen nor-
mal subjects were used as controls. Both groups re-
ceived large doses of chiorothiazide for one to two
weeks. In each of the hypertensive patients, glucose
intolerance became more pronounced after thiazides.
Five of the 15 developed symptomatic diabetes mel-
titus. In contrast, there was no change in the normal
subjects. The hypertenisve patients also displayed a
lesser decline of blood sugar in response to i.v. tol-
butamide after thiazide administration. Since serum
potassium declined less than 0.5 mEq/liter, the au-
thors did not ascribe deterioration of glucose toler-
ance to potassium deficiency.
Sagild, Andersen, and Andreasen examined the ef-
fect of experimental potassium deficiency on glucose
utilization in five normal subjects [771. In each, the
rate of glucose utilization decreased. Despite potas-
sium deficits ranging from 200 to 500 mEq, however,
serum potassium remained normal in two and fell to
3.0 mEq or less in three of the five subjects. Such
evidence supports the notion that the total deficit of
potassium is not necessarily reflected by frank hypo-
kalemia.
Rapoport and Hurd [78] studied the effect of
chlorothiazide treatment in 15 patients who had ei-
ther a family history of diabetes or confirmed mild
glucose intolerance. Seven developed glucose intoler-
ance after receiving thiazides for one week. Potas-
sium chloride supplements corrected the glucose in-
tolerance even if thiazides were continued. The
subjects whose glucose intolerance became abnormal
showed a greater decline of serum potassium. Their
average values for serum potassium before and after
thiazides were 4.6 mEq/liter and 3.4 mEq/liter, re-
spectively. In those who demonstrated no abnor-
mality, comparable values were 4.7 mEq/liter and 4.2
m Eq/liter.
Conn [791 examined patients with primary aldoste-
ronism before and after administration of supple-
mental potassium or after operative correction. He
was the first to show clearly that glucose intolerance
was associated with subnormal insulin production
and that both were corrected by either potassium
supplementation or surgical correction of the aldoste-
ronism. His studies also showed that serum potas-
sium concentration did not reliably reflect total body
potassium stores.
Based upon the material presented [76—79], it
would appear that clinically important carbohydrate
intolerance associated with diuretic therapy is most
apt to occur in patients who already have either frank
diabetes or at least the preclinical disease. Perhaps
related to insulin deficiency, their serum potassium
concentration may not become frankly low, and
therefore, potassium deficiency may not be suspected.
Although never examined, my own observations sug-
gest that patients with diabetes mellitus and glyco-
suria, who have associated hypertension in contrast
to uncomplicated hypertensives, are much more
likely in incur potassium deficiency as a result of
diuretic therapy. If volume contraction secondary to
diuretics increases production of aldosterone, en-
hanced delivery of sodium to the distal nephron in
the wake of the osmotic diuresis associated with
glycosuria could conceivably enhance the rate of po-
tassium loss. Furthermore, if significant potassium
deficiency should occur in such patients, especially
those with adult onset diabetes, it seems possible that
their already marginal insulin production would be-
come further depressed.
An additional factor that could impair carbohy-
drate utilization in potassium deficiency is produc-
tion of an abnormal molecular species of insulin.
Thus, Gorden, Sherman, and Simopoulos [65] have
shown that the poorly-active, pro-insulin fraction of
total insulin released from the pancreas is increased
in potassium deficiency.
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Studies from this laboratory [6, 801 have shown
that some patients with end-stage renal disease,
whose serum potassium concentration is clearly nor-
mal, may display moderate total body potassium
deficits. Each of these patients showed impaired abil-
ity to utilize glucose. Each showed an abnormally
elevated glucagon [8 1]. Conventional hemodialysis
for several weeks restored glucose utilization to nor-
mal. Of interest, glucagon remained elevated and
there was no apparent alteration of total insulin ac-
tivity in plasma. Muscle and total body potassium
content, however, rose after dialysis. Although the
rise of body potassium may have facilitated im-
provement in glucose utilization, it is impossible to
positively assign the improvement to this change.
Thus, recent studies have shown that the molecular
species of both insulin [82] and glucagon [83] in
patients with renal failure may be abnormal. Such
information obscures interpretation as to whether or
not deficiency of "normal" insulin results in a higher
set for serum potassium concentration in renal failure
as it apparently does in patients with diabetes mel-
litus. That Westervelt observed a normal movement
of potassium in response to insulin in patients with
renal failure [84] suggests that a true insulin defi-
ciency may exist. Obviously, a considerable amount
of work needs to be done on this important derange-
men t.
Reprint requests to Dr. 2. P. Knochel, Department of Internal
Medicine, flniversijr of Texas, Southwestern Medical School, Dal-
las, lxas 75235, U.S.A
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